Work

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

Year: 2014

Type: article

Abstract: Meeting abstracts Treatment options for metastatic urothelial bladder cancer (UBC) are limited. Mutational complexity is known to be high in UBC and may correlate with increased immunogenicity. MPDL3280A, a human PD-L1 monoclonal antibody containing an engineered Fc-domain designed to promote a Th1

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-2-s3-p131

Authors: Yuanyuan Xiao, Christina Rabe, Marcin Kowanetz, Thomas Powles, Nicholas J Vogelzang, Daniel P Petrylak, Yohann Loriot, Mitchell Denker, Rin Nakamura, Qun J Wu, Teiko Sumiyoshi, Zachary Boyd, Siew-leng M Teng, Xiaodong Shen, Gregg Fine, Daniel S Chen, Priti S Hegde

Institutions: Genentech, F. Hoffmann-La Roche AG, Queen Mary University of London, Barts Cancer Institute, University of Nevada, Reno, Comprehensive Cancer Centers of Nevada, Yale Cancer Center, Institut Gustave Roussy, Fondation Gustave Roussy

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

OpenAlex ID: W2037556077

FWCI: 0.322

Cites:

Cited by: 5

Related to: 10